The estimated Net Worth of Elizabeth G. O'farrell is at least $95 Million dollars as of 24 August 2023. Ms. farrell owns over 13,186 units of PDL Biopharma Inc stock worth over $94,549,320 and over the last 6 years she sold PDLI stock worth over $213,648. In addition, she makes $270,040 as Chairperson of the Board at PDL Biopharma Inc.
Sign up
Ms. Farrell PDLI stock SEC Form 4 insiders trading
Elizabeth has made over 5 trades of the PDL Biopharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 13,186 units of PDLI stock worth $30,064 on 24 August 2023.
The largest trade she's ever made was selling 63,291 units of PDL Biopharma Inc stock on 18 November 2020 worth over $150,633. On average, Elizabeth trades about 7,220 units every 78 days since 2018. As of 24 August 2023 she still owns at least 26,220 units of PDL Biopharma Inc stock.
You can see the complete history of Ms. farrell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elizabeth O'Farrell biography
Elizabeth G. O'Farrell serves as Chairperson of the Board of the Company. Ms. O’Farrell previously served 24 years with Eli Lilly and Company (“Eli Lilly”), most recently as Chief Procurement Officer from 2012 to 2017, until her retirement. At Eli Lilly, she advanced through various executive management positions, including Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products and auditor at Whipple & Company and Price Waterhouse. Currently, she serves on the Board of Directors of Geron Corporation and Inhibikase Therapeutics, Inc. Ms. O’Farrell served as a Board member of the YMCA of Greater Indianapolis from 2006 until 2017, including as its chairperson from 2014 to 2016. She is a member of the Finance Committee of the United Way of Brevard, in Brevard County, FL., and previously served on the Boards of the Washington Township Schools Foundation and Keep Indianapolis Beautiful. Ms. O’Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University.
What is the salary of Elizabeth Farrell?
As the Chairperson of the Board of PDL Biopharma Inc, the total compensation of Elizabeth Farrell at PDL Biopharma Inc is $270,040. There are 5 executives at PDL Biopharma Inc getting paid more, with Dominique Monnet having the highest compensation of $6,701,000.
How old is Elizabeth Farrell?
Elizabeth Farrell is 56, she's been the Chairperson of the Board of PDL Biopharma Inc since 2020. There are 3 older and 3 younger executives at PDL Biopharma Inc. The oldest executive at PDL Biopharma Inc is John McLaughlin, 68, who is the Director.
What's Elizabeth Farrell's mailing address?
Elizabeth's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Insiders trading at PDL Biopharma Inc
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain, and Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
What does PDL Biopharma Inc's logo look like?
Complete history of Ms. farrell stock trades at Geron, PDL Biopharma Inc, and Inhibikase Therapeutics
PDL Biopharma Inc executives and stock owners
PDL Biopharma Inc executives and other stock owners filed with the SEC include:
-
Dominique Monnet,
President, Chief Executive Officer, Director -
Christopher Stone,
Vice President, General Counsel, Secretary -
Edward Imbrogno,
Chief Financial Officer, Chief Accounting Officer, Vice President - Finance -
John McLaughlin,
Director -
David Gryska,
Independent Director -
Elizabeth O'Farrell,
Chairperson of the Board -
Natasha Hernday,
Independent Director -
Alan Bazaar,
Independent Director -
Danny J Jr. Hart,
Assoc Genl Counsel/Asst Sec -
Samuel R Saks,
Director -
Jody S Lindell,
Director -
Paul R Edick,
Director -
Harold E Selick,
Director -
Paul W Sandman,
Director -
Peter S Garcia,
Vice President, CFO -
Steffen Pietzke,
Controller and CAO -
Shlomo Yanai,
Director -
Jill M. Jene,
VP, Business Development -
Christine R Larson,
VP & Chief Financial Officer -
Joseph Iii Klein,
Director -
Karen J Wilson,
VP of Finance & PAO -
Mark Anthony Mc Camish,
SVP & CMO -
Brett L Schmidli,
SVP, Technical Operations -
Gary A Lyons,
Director -
Andrew Guggenhime,
SVP & Chief Financial Officer -
Faheem Hasnain,
President & CEO -
Francis Willard Sarena,
Exec Dir/Chief Legal Off/Secy -
Herb Cross,
Corp Controller/Prin Acctg Off -
Richard /Ca/ Murray,
Sr. VP & CSO -
Steven E Benner,
SVP and Chief Medical Officer -
Bradford S Goodwin,
Director -
Laurence Jay Korn,
Chairman of the Board -
Karen A Dawes,
Director -
Jaisim Shah,
Vice President, Marketing -
Jon S Saxe,
Director -
L Patrick Gage,
Director -
Glen Y Sato,
SVP and CFO -
Cynthia Lynn Shumate,
VP Legal Affrs, Secy & CCO -
Cary L Queen,
Senior Vice President -
Peter H Calcott,
VP, Quality & Compliance -
Laurie C Torres,
VP, Human Resources -
David Iwanicki,
VP, Sales & Sales Operations -
Mark Mcdade,
Chief Executive Officer -
Robert Michael Ii Savel,
SVP Technical Operations -
Samuel Broder,
Director -
George Jue,
VP, Fin & Corp. Controller -
Max Link,
Director -
Sergio Garcia Rodriguez,
VP, Legal and General Counsel -
Lyn D Olson,
VP, Quality and Compliance -
Douglas O Ebersole,
SVP, Legal & Corp Development -
George M Gould,
Director -
Jurgen Drews,
Director -
Behrooz Najafi,
V.P. IS and Corporate Services -
Corine Klingbell,
VP, Preclinical Development -
William R Benjamin,
VP, Research & Clinical Tech -
Frances G Charlson,
VP, Human Resources -
Patrick M Caldwell,
VP, Finance and Controller -
Mark P Backer,
VP, Technical Development -
David Montez,
Controller and CAO -
Fred Frank,
Director -
Bruce Tomlinson,
Chief Financial Officer -
Caroline J Krumel,
Vice President of Finance -
Point Capital L.P.O'shea Ro...,